Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacilli cluster xvii strain relative clostridium aq innocuum live
- Development stage
- Unknown
- Lead developer
- Vedanta Biosciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
bacilli cluster xvii strain relative clostridium aq innocuum live is a specific live bacterial strain belonging to the Clostridia Cluster XVII, identified as a relative of *Clostridium innocuum*. It is a key component of **VE303**, a defined live biotherapeutic product (LBP) consortium developed by **Vedanta Biosciences**. VE303 is composed of eight distinct, clonal commensal bacterial strains that work synergistically to restore the gut microbiota and provide colonization resistance against *Clostridioides difficile*. This specific strain contributes to the therapeutic effect by competing with *C. difficile* for essential nutrients and producing metabolites that inhibit the pathogen's growth and toxin production. It is currently being evaluated in Phase 3 clinical trials as part of the VE303 consortium for the prevention of recurrent *Clostridioides difficile* infection (rCDI) and in Phase 2 for hepatic encephalopathy.
- Other names
- Clostridia cluster XVII strainClostridium innocuum relative strain
Beyond the preview
Go deeper on bacilli cluster xvii strain relative clostridium aq innocuum live.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacilli cluster xvii strain relative clostridium aq innocuum live.